Exelixis (EXEL) Jefferies Global Healthcare Conference 2025 summary

Strategic pipeline and clinical development

• Significant momentum following resolution of patent issues and a major collaboration with Merck, with six pivotal studies for Zanzalintinib underway and two expected to read out later this year.

• Zanzalintinib is designed to replicate the efficacy of Cabo with a shorter half-life, aiming for better combinability and patient management, especially in adverse event scenarios.

• The development strategy leverages extensive Cabo data to accelerate Zanza's progress, focusing on areas where a more user-friendly TKI could be advantageous.

• The company is pursuing a broad development plan for Zanza, with expectations for multiple future study waves beyond the current six pivotal trials.

• Partnerships, particularly with Merck, are structured for risk and cost sharing, enabling capital-efficient expansion of the clinical program.

Market opportunity and financial outlook

• Zanza's total addressable market is estimated at $5 billion, with roughly 45% in GI, 45% in GU, and 10% in head and neck cancers.

• The CRC market is valued at about $1 billion, split evenly between patients with and without liver metastases, with earlier market entry favored by recent trial amendments.

• The company sets conservative market share expectations, aiming for realistic penetration rates (e.g., 10-15% in head and neck), with upside potential if the market expands.

• Commercial performance in first-line RCC continues to grow, driven by strong data updates and a focused commercial team.

• Early signs in the NETs launch are positive, with physician familiarity aiding adoption, though no immediate bolus in uptake is expected.

Clinical trial design and differentiation

• Recent amendments to the CRC 303 study allow for earlier and broader interim analysis, increasing the probability of success and market entry speed.

• Zanza's differentiation is expected to manifest in improved patient management, fewer discontinuations, and potentially better efficacy due to its shorter half-life.

• The focus is on demonstrating superiority or differentiation versus current standards of care (e.g., regorafenib, sunitinib, pembrolizumab, everolimus) rather than direct comparison to Cabo.

• In head and neck cancer, the company is leveraging learnings from prior studies and aiming for realistic, data-driven market projections.

• Future studies may target post-PD1 and specific subpopulations, with Zanza positioned as a backbone therapy across multiple tumor types.